BAJAJ BROKING
Biocon Ltd announced its subsidiary’s approval from NMPA China for Tacrolimus capsules. The drug will strengthen its portfolio and bolster its global market presence. Biocon Ltd share price rose by 1.13% post-announcement.
Biocon Pharma Ltd, a wholly owned subsidiary of Biocon Ltd, has received approval from the National Medical Products Administration (NMPA) in China for its Tacrolimus capsules in strengths of 0.5mg, 1mg, and 5mg. Tacrolimus, an immunosuppressant drug, is primarily used to prevent organ rejection in transplant patients by modulating the immune system.
Also read: Avenue Supermarts Reports 17.5% Revenue Growth in Q3 FY25
Approval Scope: Tacrolimus capsules approved in 0.5mg, 1mg, and 5mg strengths.
Therapeutic Use: Prevents organ rejection in transplant patients.
Global Presence: Enhances Biocon’s portfolio in complex drugs.
Also read: Wockhardt’s Miqnaf Gains CDSCO Approval for CABP Treatment
Metric | Q2 FY25 | Q2 FY24 | Change (YoY) |
Net Profit | ₹27.1 crore | ₹172 crore | -84.2% |
Revenue from Operations | ₹3,590.4 crore | ₹3,462 crore | +3.7% |
EBITDA | ₹685.5 crore | ₹741.3 crore | -7.6% |
This approval marks a strategic milestone for Biocon, as it further strengthens the company’s portfolio of complex drugs and expands its reach in the global pharmaceutical market. With the Chinese market’s regulatory clearance, Biocon can expedite the commercialisation of Tacrolimus capsules in the region.
Following the announcement, Biocon Ltd share price increased by 1.13%, closing at ₹372.95 on the BSE. This reflects investor confidence in Biocon’s ongoing efforts to expand its global footprint and enhance its portfolio.
Biocon’s NMPA approval for Tacrolimus capsules demonstrates its commitment to innovation and global expansion. The move further cements Biocon’s position as a leader in the biotechnology and pharmaceutical sectors, with promising prospects for future growth.
Also read: IRFC Partners REMCL to Fund Renewable Energy for Railways
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
PPF vs Mutual Fund Investment: Which is Better for You?
04 Jan, 2025 | 7 Min. read
How to Apply for Standard Glass Lining IPO & Check Allotment Status?
04 Jan, 2025 | 1 Min. read
How to Apply for Indobell Insulations IPO & Check Allotment Status?
04 Jan, 2025 | 1 Min. read
Know the Objective & Analysis of Indobell Insulations IPO
04 Jan, 2025 | 3 Min. read
Reasons for Missing Out on an IPO Allotment
04 Jan, 2025 | 7 Min. read
IPO Performance in India - List of Successful IPOs in 2024
04 Jan, 2025 | 3 Min. read
Quadrant Future Tek IPO- Key Objective & Deep Analysis
04 Jan, 2025 | 4 Min. read
Gold Price in India | Gold Rises 1.2% to $2,671.50; Silver Gains 2.6%
03 Jan, 2025 | 40 Min. read
Avenue Supermarts Reports 17.5% Revenue Growth in Q3 FY25
03 Jan, 2025 | 2 Min. read
What’s the Minimum Amount for Mutual Fund Investments?
03 Jan, 2025 | 6 Min. read
Biocon Gets China NMPA Approval for Tacrolimus Capsules
03 Jan, 2025 | 2 Min. read
Wockhardt’s Miqnaf Gains CDSCO Approval for CABP Treatment
03 Jan, 2025 | 2 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading